Soft tissue sarcomas in the first year of life

Iyad Sultan1, Michela Casanova, Usama Al-Jumaily

  • 1Department of Pediatric Oncology, King Hussein Cancer Center, Amman, Jordan. isultan@khcc.jo

European Journal of Cancer (Oxford, England : 1990)
|June 12, 2010
PubMed

Insights

Infantile soft tissue sarcomas (STS) have poorer survival rates than in older children. Specific subtypes like fibrosarcoma and haemangiopericytoma show better outcomes, while reduced radiotherapy use may impact survival.

Area of Science:

  • Pediatric Oncology
  • Cancer Epidemiology
  • Pediatric Pathology

Background:

  • Infantile soft tissue sarcomas (STS) are rare, posing therapeutic challenges in very young patients.
  • Optimal treatment delivery is crucial for improving outcomes in this vulnerable population.

Purpose of the Study:

  • To analyze the clinical features and survival of infants diagnosed with STS.
  • To compare infantile STS with those in older children to identify prognostic differences.

Main Methods:

  • Utilized the SEER database to identify STS cases in infants (<1 year) diagnosed between 1973-2006.
  • Analyzed clinical characteristics, including incidence, metastatic rates, and histology.
  • Compared survival outcomes and treatment modalities (e.g., radiotherapy) between infantile and older pediatric STS patients.

Main Results:

  • The incidence of infantile STS was 16.0 per million, representing 7.3% of pediatric malignancies.
  • Rhabdomyosarcoma, fibrosarcoma, malignant rhabdoid tumors, and haemangiopericytoma were the most common histologies.
  • Infantile STS showed significantly worse 5-year survival (62%) compared to older children (71%), with metastasis and certain histologies being adverse prognostic factors. Radiotherapy use was significantly lower in infants.

Conclusions:

  • Infantile STS, as a group, exhibit poorer survival rates compared to older children.
  • Histologic subtype significantly influences outcomes, with infantile fibrosarcoma and haemangiopericytoma demonstrating better prognoses.
  • The reduced utilization of radiotherapy in infants may contribute to inferior survival outcomes.
Abstract

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...